Immunovant, Inc. (IMVT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$39.25+0.33%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IMVT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||||
| R&D Expenses | — | — | — | — | — | 101.8 | 68.6 | 47.9 | 47.9 |
| Operating Income | — | — | — | — | (211.0) | (156.8) | (107.8) | (66.3) | (66.3) |
| Earnings from Continuing Operations | |||||||||
| Interest Expense | — | — | — | — | — | — | 0.0 | 0.6 | 0.6 |
| EBT, Incl. Unusual Items | (538.9) | (505.4) | (412.9) | (258.8) | (211.0) | (156.8) | (107.8) | (66.3) | (66.3) |
| Income Tax Expense | — | 0.2 | 0.9 | 0.6 | 0.0 | (0.1) | (0.4) | 0.1 | 0.1 |
| Net Income | |||||||||
| Net Income | (538.2) | (505.6) | (413.8) | (259.3) | (211.0) | (156.7) | (107.4) | (66.4) | (66.4) |
| Per Share | |||||||||
| Basic EPS | (2.62) | (2.77) | (2.73) | (1.88) | (1.71) | (1.43) | (1.22) | — | — |
| Diluted EPS | (2.62) | (2.77) | (2.73) | (1.88) | (1.71) | (1.43) | (1.22) | — | — |
| Basic Weighted Avg Shares | 205.5 | 182.4 | 151.6 | 138.1 | 123.1 | 109.7 | 87.8 | — | — |
| Diluted Weighted Avg Shares | 205.5 | 182.4 | 151.6 | 138.1 | 123.1 | 109.7 | 87.8 | — | — |
| Supplemental | |||||||||
| EBIT | — | — | — | — | (211.0) | (156.8) | (107.8) | (66.3) | (66.3) |
| Effective Tax Rate | — | — | — | — | -0.0% | 0.1% | 0.3% | -0.1% | -0.1% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.